论文部分内容阅读
目的:探讨双虎清肝颗粒联合恩替卡韦片治疗慢性乙型肝炎临床疗效及安全性,旨在探讨最佳治疗方案。方法:按照随机数字表法将80例慢性乙肝患者分为对照组40例予恩替卡韦片治疗与治疗组40例,于对照组治疗基础上加用双虎清肝颗粒治疗。统计两组患者治疗第4周时临床主要症状及体征改善情况(乏力、口苦口干、食欲不振、腹胀、肝区不适);通过血液检测来比较两组患者ALT复常及H B V-D N A水平下降情况。结果:治疗组治疗第4周时主要症状、体征改善率均高于对照组(P<0.05)。治疗组治疗后ALT复常率、HBV-DNA水平较基线下降率均高于对照组(P<0.05)。结论:双虎清肝颗粒联合恩替卡韦片治疗慢性乙型肝炎疗效显著且安全。
Objective: To investigate the clinical efficacy and safety of Shuanghu Qinggan granules combined with entecavir tablets in the treatment of chronic hepatitis B, and to explore the best treatment plan. Methods: Eighty patients with chronic hepatitis B were divided into control group (n = 40) and entecavir tablet (n = 40) according to the random number table method. The treatment group was treated with double tiger qinggan granule on the basis of the control group. The main clinical symptoms and signs of improvement (fatigue, mouth and mouth dryness, loss of appetite, abdominal distension, liver discomfort) in the two groups at the 4th week of treatment were statistically analyzed. The levels of ALT and HBVDNA in the two groups were compared by blood test Happening. Results: At the 4th week of treatment, the main symptoms and signs of improvement were higher than those of the control group (P <0.05). After treatment, the ALT normalization rate and the HBV DNA level in the treatment group were significantly lower than those in the control group (P <0.05). Conclusion: The treatment of chronic hepatitis B with Shuanghu Qinggan granules combined with entecavir tablets is effective and safe.